AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02055976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Atorvastatin plus Ezetimibe 10 mg oral administration once daily for 16 week (open)
Study NCT02055976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bococizumab (PF-04950615;RN316)
Description: 50 mg Q14D SC for 16 week
Study NCT02055976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bococizumab (PF-04950615;RN316)
Description: 100 mg Q14D SC for 16 week
Study NCT02055976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bococizumab (PF-04950615;RN316)
Description: 150 mg Q14D SC for 16 week
Study NCT02055976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Q14D SC for 16 week
Study NCT04748250 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture needles
Description: Standard acupuncture needle which is 3 cm long with diameter o.3 mm
Study NCT04748250 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy phytoestrogens
Description: 100 millilitre of soy milk every day or 100 gram of cooked soy beans per day.
Study NCT02256150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mizoribine (MZR)
Study NCT02256150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (CTX)
Study NCT03696498 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resin restoration (1 step)
Description: Permanent resin restoration is placed on top of the partial removed caries.
Study NCT03696498 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resin restoration (2 steps)
Description: A calcium hydroxide containing base material is used and a temporary glass-ionomer restoration is placed in the entire cavity. After 4-6 months the patients are recalled. The temporary restoration is removed and final excavation is carried out with hand excavators until firm but stained dentine remains. A permanent resin restoration is performed.
Study NCT03831607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7791
Description: KHK7791 30 mg, 20 mg ,10 mg or 5 mg tablets
Study NCT03342352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat administered orally at the protocol-defined dose twice daily.
Study NCT03342352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for epacadostat administered orally twice daily.
Study NCT03342352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for 6 cycles.
Study NCT03342352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for 6 cycles.
Study NCT03342352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for 6 cycles.
Study NCT03342352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for 6 cycles.
Study NCT03342352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab administered intravenously at the protocol-defined dose weekly.
Study NCT03342352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-Fluorouracil administered intravenously at the protocol-defined dose on Days 1-4 for 6 cycles.
Study NCT03342352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 5-Fluorouracil administered intravenously at the protocol-defined dose on Days 1-4 for 6 cycles.
Study NCT00229580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 session brief intervention with health behavior feedback
Study NCT00229580 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual
Study NCT01825278 — intervention group
Intervention type: DEVICE
Intervention: ExSpiron Respiratory Volume Monitor (RVM, ExSpiron™, Respiratory Motion, Inc.; Waltham, MA
Description: Monitoring sensors will be applied to patient's right chest and the monitoring device will collect breathing parameters such as breathing rate and volumes before, during and after the procedure until patient is ready to leave the recovery room. At the beginning and at the end of the study investigator will perform a one-time measurement of patient's respiratory parameters using a standard handheld spirometer. This is a non-invasive device that is commonly used in clinical care not related to research.
Study NCT04104074 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Arm 1: The single radiotherapy dose was 200cGy, once a day, and the total dose was 5000cGy.~Arm 2: the single dose of radiotherapy was 300 cGy, once a day, and the total dose was 3000 cGy.
Study NCT04104074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab is a PD-1 inhibitor, intravenously, at a dose of 200 mg, once every 3 weeks
Study NCT02103374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atrovent + Bricanyl or Atrovent + Ventoline
Description: 3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form during 48 weeks
Study NCT02103374 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule lactose during 48 weeks
Study NCT01328262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calculated red blood cell transfusion
Description: The subjects receive an amount of red blood cells that has been calculated from their body surface area.
Study NCT01328262 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard red blood cell transfusion
Description: The subjects in this group receive the prescribed number of red blood cell units.
Study NCT03160469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intragastric Elipse Device
Description: Obesity prevalence is increasing worldwide, and Kuwait is currently considered to be the country with the most obese population1. Accordingly, standardization of the weight loss procedures has been made according to the Body Mass Index (BMI), keeping the more advanced surgeries for class II obesity (BMI 35- 39.9) and above, with consideration of other factors like, for example, obesity-related comorbidities. For those patients whom considered in the category of overweight (BMI = 25- 29.9) \& class I obesity (BMI 30- 34.9), after failure of diet attempts, the weight loss options are limited. Of the highly requested options are the various types of intra-gastric balloons. Conventional endoscopic gastric balloons have proven to be safe and effective, with Excess Weight Loss (%EWL) of 25-50%2. A new swallowable gastric balloon, named Elipse, has been launched recently in Kuwait and became highly popular due to its unique concept of being procedure-less.
Study NCT01878669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Study NCT01878669 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT01305603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: On both sides of the abdomen 30 ml of bupivacaine 2.5 mg/ml will be injected. This is a total of 60 ml of bupivacaine 2.5 mg/ml.
Study NCT01305603 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Injection
Description: Injection under ultrasound-guidance
Study NCT01592942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Histoacryl
Description: cyanoacrylate glue fixation of mesh 1 ml
Study NCT01592942 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Progrip
Description: self-gripping mesh
Study NCT01592942 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sutures (prolene 3-0)
Description: non-absorbable suture fixation 3-0
Study NCT01790763 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Keramatrix
Description: Dressing for second degree burn
Study NCT04577079 — intervention group
Intervention type: DEVICE
Intervention: Evaluation of the need of emergency medical services
Description: The main aim of this study is to validate the use of IPFM in a hospital setting by evaluating the association of IPFM output with 1) clinical urgency and severity of the conditions (using Emergency Severity Index \[ESI\], an international triaging protocol for emergency units, and an assessment by triage nurse); and 2) actual diagnoses made by the hospital doctors. The objective is also to assess the correlation of IPFM output with redirection or referral to various specialties
Study NCT04878744 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shmapped
Description: Novel app-based intervention to improve wellbeing in patients with common mental health problems.
Study NCT04878744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shmapped
Description: Novel app-based intervention to improve wellbeing in patients with common mental health problems.
Study NCT05186441 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DMPFC iTBS
Description: The intermittent theta-burst stimulation (iTBS) (i.e. two excitatory intervention paradigm) to target DMFPC can improve out-of-control behavior and decision-making model.
Study NCT05186441 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: DMPFC iTBS
Description: The intermittent theta-burst stimulation (iTBS) (i.e. two excitatory intervention paradigm) to target DMFPC can improve out-of-control behavior and decision-making model.
Study NCT05186441 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DLPFC iTBS
Description: The intermittent theta-burst stimulation (iTBS) to target DLFPC (i.e. region within the executive control network) can effectively reduce craving, which is probably associated with enhancement of executive function.
Study NCT05186441 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: DLPFC iTBS
Description: The intermittent theta-burst stimulation (iTBS) to target DLFPC (i.e. region within the executive control network) can effectively reduce craving, which is probably associated with enhancement of executive function.
Study NCT03024138 — intervention group
Intervention type: RADIATION
Intervention: Repeat CT scan
Study NCT01052961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: oseltamivir 150 mg bd for 5 days
Study NCT01605942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Drug Delivery System
Description: Dexamethasone Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
Study NCT01605942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Drug Delivery System
Description: Placebo Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
Study NCT03641846 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DornierAries2 LiST device + 5 mg Tadalafil
Description: All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Tadalafil 5mg. Total treatment period = 4 weeks
Study NCT03641846 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DornierAries2 LiST device + Placebo Pill
Description: All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Placebo pills. Total treatment period = 4 weeks.
Study NCT02033213 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive group
Description: A group of patients who received ≤ 8ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.~The fluid administered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.
Study NCT02033213 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liberal group
Description: A group of patients who received > 8 ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.~The fluid admnistered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.
Study NCT01866033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765 (Treatment A)
Description: 560 mg capsules administered by mouth on Day 1, Period 1
Study NCT01866033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765 (Treatment B)
Description: 560 mg capsules administered by mouth (without grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule
Study NCT01866033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765 (Treatment C)
Description: 140 mg capsule administered by mouth (with grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule
Study NCT01866033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13C6 PCI-32765 (reference)
Description: 100 mcg administered intravenously 2 h after study drug
Study NCT03130426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iGlarLixi
Description: Dose is titrated to achieve fasting normoglycemia
Study NCT03130426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: In those who need additional insulin or who cannot tolerate iGlarLixi, insulin glargine will be used. Dose is titrated to achieve fasting normoglycemia.
Study NCT03130426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Dose is titrated to 2000 mg daily or maximal tolerated dose
Study NCT03130426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle therapy
Description: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
Study NCT01790763 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex
Description: Dressing for second degree wound
Study NCT01766349 — intervention group
Intervention type: BEHAVIORAL
Intervention: respiratory muscle performance
Description: Respiratory muscle performance will include measurements of respiratory muscle strength and pulmonary function testing.
Study NCT02714361 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 supplement
Description: 1500 IU (37.5 mcg) Vitamin D3 capsules daily over 8 weeks (56 days)
Study NCT02714361 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 65% olive oil capsules daily over 8 weeks (56 days)
Study NCT04206553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dupilumab
Description: Loading dose administered subcutaneous (SC), followed by SC once every 2 weeks (Q2W) dosing.
Study NCT04206553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Matching dupilumab without active substance
Study NCT04206553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids (OCS)
Description: Prednisone or prednisolone per standard of care to obtain control of disease activity.
Study NCT01748474 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Supplemental oxygen via a mask
Study NCT01748474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen via a mask
Study NCT02834585 — intervention group
Intervention type: OTHER
Intervention: Ultrasound
Study NCT02094027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Self Help
Description: A behaviourally orientated guided self help book designed to reduce binge eating prior to surgery
Study NCT02094027 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment As Usual
Description: Binge eating disordered participants receive treatment as usual in the form of bariatric surgery (i.e. no pre-operative intervention to reduce binge eating)
Study NCT03085004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol
Description: The cyst will be lavaged for 3 to 5 minutes using >/=99% ethanol as the lavage agent prior to infusing the cyst with the paclitaxel + gemcitabine admixture.
Study NCT03085004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: The cyst will be lavaged for 3 to 5 minutes using normal saline as the lavage agent prior to infusing the cyst with the paclitaxel + gemcitabine admixture.
Study NCT04264598 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Commercialized sIPV
Description: The commercialized sIPV was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.The antigen contents of type I, type II and type III polioviruses in the commercialized sIPV were 30 DU, 32 DU and 45 DU. The vaccine was in liquid form, 0.5 ml per dose.
Study NCT04264598 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Commercialized IPV
Description: The commercialized Salk IPV was manufactured by Sanofi Pasteur S.A.The antigen contents of type I, type II and type III polioviruses in the commercialized IPV were 40 DU, 8 DU and 32 DU. The vaccine was in liquid form, 0.5 ml per dose.
Study NCT01457066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Navigator Intervention
Description: Peer navigators will teach HIV retention and linkage skills and knowledge using group-based as well as one-on-one, peer-based learning approaches.
Study NCT01045642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole Magnesium DR Capsules 20 mg
Study NCT01045642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Omeprazole Magnesium DR Capsules 20 mg
Study NCT00597766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: One-time Screening/Eligibility Neer's Test: 5 cc of 2% lidocaine
Study NCT00597766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: One-time Screening/Eligibility Neer's Test: 5 cc of 2% lidocaine
Study NCT00597766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone + Lidocaine
Description: Low Dose -- One-time injection of 20 mg triamcinolone: 1.5 cc of normal saline, 0.5 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
Study NCT00597766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone + Lidocaine
Description: Standard Dose -- One-time injection of 40 mg triamcinolone: 1 cc of normal saline, 1 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
Study NCT00597766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone + Lidocaine
Description: High Dose -- One-time injection of 60 mg triamcinolone: 0.5 cc of normal saline, 1.5 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
Study NCT03577704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07+Gemcitabine+Cisplatin
Description: Recombinant anti-EGFR humanized monoclonal antibody in combination with Gemcitabine and Cisplatin.~HLX07, IV, weekly.
Study NCT03577704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07+Paclitaxel+Carboplatin
Description: Recombinant anti-EGFR humanized monoclonal antibody in combination with Paclitaxel and Carboplatin.~HLX07, IV, weekly.
Study NCT03577704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07+mFOLFOX6
Description: Recombinant anti-EGFR humanized monoclonal antibody in combination with Oxaliplatin, Calcium Folinate and 5-FU.~HLX07, IV, weekly.
Study NCT03566823 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ontamalimab
Description: Subcutaneous injection of ontamalimab will be administered using a prefilled syringe.
Study NCT03566823 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of placebo matched with ontamalimab will be administered using a prefilled syringe.
Study NCT01622361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adriamycin+Cyclophosphamide>Docetaxel
Description: 1. Adriamycin 60mg/m2 + Cyclophosphamide 600mg/m2~   * Route: by slow intravenous bolus~  * Schedule: every 3weeks for 4 cycle~2. Docetaxel 75mg/m2~   * Route: intravenous as per local practice~  * Schedule: every 3weeks for 4 cycle
Study NCT01622361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRHa with Tamoxifen
Description: 1. Goserelin(GnRHa) 3.6mg~   * Route: subcutaneously under the abdominal skin~  * Schedule: every 4weeks for 6cycles (period of 34 days between 2 administrations must not be exceeded)~2. Tamoxifen 20mg/day~   * Route: Oral~  * Schedule: everyday